Stem cell applications in regenerative medicine for stress urinary incontinence: A review of effectiveness based on clinical trials

Abstract

Objective To evaluate the current state, therapeutic benefit and safety of urethral injection of autologous stem cells for the treatment stress urinary incontinence (SUI). Materials and methods A selective database search of PubMed, the Excerpta Medica dataBASE (EMBASE), Cochrane Library and Google Scholar was conducted to validate the effectiveness of stem cell-based therapy. The search included clinical trials published up until 4 January 2020, written in English, and included cohorts of women and men who had received stem cell-based therapy for SUI. The search used the following keywords in various combinations: ‘stem cell therapy’, ‘cell-based therapy for SUI’, ‘regenerative medicine for SUI’, and ‘tissue engineering’. The success rates were assessed according to cough test, urodynamics, pad tests, and International Consultation on Incontinence Questionnaire-Urinary Incontinence. The primary endpoint was continence rate to measure objectively the effect of the treatment. Results We identified four clinical trials using local injections of adipose-derived stem cells (ADSCs), 11 trails with muscle-derived stem cells (MDSCs), and two trails with human umbilical cord blood stem cells (HUCBs) and total nucleated cells (TNCs). The median improvement rate of intrinsic sphincter deficiency after ADSCs, MDSCs, TNCs, HUCBs injections were 88%, 77%, 89%, 36% (improvement rate: 1–2 pads) at a mean (range) follow-up of 6 (1–72) months. The cell sources, methods of cell processing, cell number, and implantation techniques differed considerably between studies. Most of the periurethral injections were at the 3, 5, 7, and 9 o’clock positions and for submucosa were at the 4, 6, and 8 o’clock positions. No significant postoperative complications were reported. Conclusion Despite many challenges in stem cell-based therapy for treating SUI, it appears to provide, in both male and female patients, acceptable functional results with minimal side-effects and complications. In the future, more clinical trials should be funded in order to optimise stem cell-based therapy and evaluate long-term outcomes. Abbreviations ADSC: adipose-derived stem cell; BMSCs: bone marrow-derived mesenchymal stem cell; CLPP: cough leak-point pressure; FPL: functional profile length; HUCB: human umbilical cord blood stem cell; ICIQ-(QOL)(SF)(UI): International Consultation on Incontinence Questionnaire (Quality of life) (-Urinary incontinence Short Form) (-Urinary Incontinence); IIQ-7: Incontinence Impact Questionnaire-short form; I-QOL: Incontinence quality of life questionnaire; ISD: intrinsic urinary sphincter deficiency; MDSC: muscle-derived stem cell; MUCP: maximum urethral closure pressure; NR: not reported; Pdet-max: maximum detrusor pressure; PVR: post-void residual urine volume; Q max : maximum urinary flow; QOL: quality of life; RP: radical prostatectomy; TNC: total nu...

Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues

“…Cell therapy of SUI is not yet a standard procedure despite many successfully completed preclinical animal studies reporting promising results 9 , 37 . Initially, only a few clinically feasible studies reported success 4 , the quality and type of cells injected varied considerably 37 , large cohort studies with the corresponding control groups were mostly missing 38 , follow-up in many studies remained rather short, and outcome was variable and not evaluated consistently. Drop-out during clinical feasibility trials seemed not to be worth reporting.…”

Autologous Muscle‐Derived Cell Therapy for Swallowing Impairment in Patients Following Treatment for Head and Neck Cancer

“…17 With the potential for self-renewal, durable proliferation, and differentiation, transplantation of these cells and their myoblast progeny has been investigated for therapeutic purposes to augment weakened muscle tissue and improve function. [7][8][9][10]18 Several studies have reported the formation of new muscle fibers following the injection of muscle-derived progenitor cells in a rodent hemiglossectomy model. [11][12][13] Kim et al injected a hydrogel-myoblast composite in a rat hemiglossectomy model and observed significant increase in tongue weight, evidence of neovascularization, and possible neurotization.…”

“…AMDC therapy involves the isolation and expansion of progenitor cells from skeletal muscle biopsies and their injection into the target muscle to induce fusion of the cells with existing myofibers and formation of new fibers to improve muscular function. Musclederived progenitor cells have recently shown benefit in treatment of stress urinary incontinence, 7,8 fecal incontinence 9 and myocardial infarction. 10 In animal studies, muscle-derived cells have successfully integrated within tissue to improve tongue strength and function.…”

Exosomes Derived by SIRT1-Overexpressing Bone Marrow Mesenchymal Stem Cells Improve Pubococcygeus Muscle Injury in Rats

“…It is well-established that stem cell therapy represents a new and prospective frontier in treatment of various diseases (22). For example, Jiang et al (23) have presented that combination with chemokine (c-c motif) receptor 1 (CCR1)-overexpressing MSCs and chemokine (c-c motif) ligand 7 (CCL7) promote the SUI recovery simulated by birth injury in rats.…”